Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyell Immunopharma, Inc.

9.69
+0.26002.76%
Post-market: 9.690.00000.00%15:47 EDT
Volume:35.84K
Turnover:341.39K
Market Cap:143.49M
PE:-0.39
High:9.81
Open:9.37
Low:9.37
Close:9.43
Loading ...

Lyell Immunopharma Inc. Completes Issuance of 625,000 Equity Milestone Shares Following ImmPACT Acquisition

Reuters
·
27 Jun

Lyell Immunopharma Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
24 Jun

Lyell Immunopharma, Inc. : H.c. Wainwright Raises Target Price to $10 From $1

THOMSON REUTERS
·
24 Jun

Lyell Immunopharma Inc. to Participate in H.C. Wainwright "HCW@Home" Series for Discussion on Innovative CAR T-Cell Therapies

Reuters
·
24 Jun

Morgan Stanley Sticks to Its Hold Rating for Lyell Immunopharma (LYEL)

TIPRANKS
·
21 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Red Cat, Nvidia Corp, Redwire

Reuters
·
18 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Verve Therapeutics, Lyell Immunopharma, Energy companies

Reuters
·
17 Jun

BUZZ-Lyell Immunopharma rises on promising data from blood cancer therapy study

Reuters
·
17 Jun

Lyell Immunopharma Announces Promising Phase 1/2 Trial Results for LYL314 in Treating Aggressive Large B-cell Lymphoma, Launches Pivotal PiNACLE Trial

Reuters
·
17 Jun

Lyell Immunopharma Inc - Lyl314 Shows 88% Overall Response Rate, 72% Complete Response Rate in 3L+ Patients

THOMSON REUTERS
·
17 Jun

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses From the Phase 1/2 Trial of Lyl314 for the Treatment of Aggressive Large B-Cell Lymphoma

THOMSON REUTERS
·
17 Jun

Lyell Immunopharma Inc - Lyl314 Has Manageable Safety Profile for Outpatient Administration

THOMSON REUTERS
·
17 Jun

Lyell Immunopharma Inc. Files Initial Beneficial Ownership Statement for General Counsel Mark Meltz

Reuters
·
12 Jun

Lyell Immunopharma Expands Board, Appoints New Director

TIPRANKS
·
10 Jun

Lyell Immunopharma Inc. Enhances Leadership Team with Key Board and Executive Appointments to Advance Cancer Therapies

Reuters
·
10 Jun

BRIEF-Lyell Immunopharma Strengthens Clinical And Commercial Capabilities With Key Board And Executive Appointments

Reuters
·
10 Jun

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities With Key Board and Executive Appointments

THOMSON REUTERS
·
10 Jun

Lyell Immunopharma trading resumes

TIPRANKS
·
02 Jun

Lyell Immunopharma trading halted, news pending

TIPRANKS
·
31 May

Lyell Immunopharma Inc - Announces 1-for-20 Reverse Stock Split - SEC Filing

THOMSON REUTERS
·
29 May